Printer Friendly

SURVIVAL TECHNOLOGY UPDATES ITS OPERATING NAME TO REFLECT EXPANDING COMMERCIAL PRODUCTS FOCUS

 SURVIVAL TECHNOLOGY UPDATES ITS OPERATING NAME
 TO REFLECT EXPANDING COMMERCIAL PRODUCTS FOCUS
 ROCKVILLE, Md., May 13 /PRNewswire/ -- Survival Technology, Inc. (NASDAQ: SURV) announced today that it is updating its operating name in order to reflect the company's expanding focus on commercial products for an increasing number of therapeutic areas and in the future will be known exclusively as STI. The company has modernized its corporate logo and identity system, to be phased in over the next year and will change its NASDAQ ticker symbol to STIQ beginning June 1, 1992.
 The corporation had previously identified itself either as Survival Technology, Inc. or STI.
 "We believe the designation STI more accurately reflects the contemporary direction and scope of the company, which now includes the development of drug delivery systems for a broad range of applications and the rapid growth of our commercial products business," said James H. Miller, president and chief executive officer of STI.
 The company pioneered the original development of auto-injector technology for the immediate self-injection of nerve gas antidote by military personnel under battlefield conditions. As a result of recent advances, however, the uses for auto-injectors are expected to broaden from emergency situations to the treatment of both acute and chronic conditions on a routine outpatient basis as well as in home- care settings.
 In addition to the recent role of auto-injectors for protection against nerve gas during Operation Desert Storm, similar STI delivery systems are currently used for the self-administration of drugs for anaphylaxis (severe allergic reactions) and cardiac arrhythmias (irregular heartbeats). Potential new therapeutic areas for auto- injector use include the delivery of drugs for migraine, impotence, anemia, thrombolysis (dissolving blood clots following heart attacks) and the growing number of biotechnology products that require injection.
 STI is developing a family of user-friendly auto-injectors to accommodate the expanding variety of injectable commercial drugs that demand safe and convenient patient administration. Each unit consists of a spring-loaded, pre-filled, pen-like device that allows the patient to inject the medication quickly, safely and reliably -- and without seeing the needle.
 "Patents for these new systems are expected to be granted in 1992, and we are already working with a number of pharmaceutical companies toward their use in the delivery of an increasing variety of drug therapies," Miller said.
 STI is also a major producer of pre-filled syringes, including the production of Toradol in its unique Cartrix syringe system for Syntex Laboratories. Toradol is a non-narcotic, intramuscular injectable widely used in hospitals for the short-term management of pain. In addition, the company has initiated a joint program with Tri/West Systems, Inc., to produce advanced, unit-dose pre-filled syringes for pharmaceutical companies.
 STI recently moved its corporate headquarters from Bethesda to new facilities in Rockville. Its new address is 2275 Research Blvd., Rockville, Md. 20850, telephone 301-926-1800.
 STI is a technology-based health care company that designs, develops and produces automatic injectors, pre-filled syringes and medical electronics, with major focus on safe and convenient participation by the patient in injection therapy. The company also supplies delivery system design, pharmaceutical research and development and sterile product manufacturing to major pharmaceutical companies worldwide.
 -0- 5/13/92
 /CONTACT: Jeffrey W. Church, chief financial officer, or Kathleen Austin, marketing, Survival Technology, 301-926-1800/
 (SURV) CO: Survival Technology, Inc. ST: Maryland IN: MTC SU:


DC -- DC012 -- 9627 05/13/92 11:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1992
Words:554
Previous Article:ATLANTA SEARS EMPLOYEE APPEARS IN NATIONAL TV SPOT
Next Article:LOS ANGELES AREA CONSUMER PRICES UP 0.2 PERCENT IN APRIL, 3.6 PERCENT FOR YEAR
Topics:


Related Articles
STI EXPANDS WORLD LEADERSHIP IN AUTO-INJECTORS WITH ACQUISITION OF MEDIMECH INTERNATIONAL
STI STRENGTHENS PRODUCT LINE, GLOBAL REACH TO BETTER POSITION FOR LONG-TERM GROWTH
SURVIVAL TECHNOLOGY, INC., REPORTS HIGHER EARNINGS FOR FISCAL 1993
STI ANNOUNCES NEW CREDIT LINE AND PRODUCT DEVELOPMENT AGREEMENTS
J. MILLER ASSUMES ADDITIONAL POST AS CHAIRMAN, PRESIDENT AND CEO OF BRUNSWICK BIOMEDICAL
STI REPORTS SECOND QUARTER EARNINGS INCREASE
STI INTERNATIONAL ENTERS AGREEMENT FOR NEW MILITARY AUTO-INJECTOR PRODUCT
STI REPORTS PROFITABLE OPERATIONS IN FISCAL 1994 THIRD QUARTER
SURVIVAL TECHNOLOGY, INC. ANNOUNCES SALE OF MEDICAL DEVICE DIVISION TO BRUNSWICK BIOMEDICAL CORPORATION
STI ELECTS J. MILLER CHAIRMAN OF BOARD

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters